Erastin: Precision Ferroptosis Inducer for Cancer Biology Research

Executive Summary: Erastin (SKU: B1524) is a small molecule that selectively induces ferroptosis, an iron-dependent, non-apoptotic cell death process, in tumor cells harboring KRAS, HRAS, or BRAF mutations (APExBIO). Erastin acts by inhibiting the cystine/glutamate antiporter system Xc⁻ and modulating the voltage-dependent anion channel (VDAC), which disrupts redox homeostasis and elevates intracellular ROS levels (Liu et al., 2022). The compound's specificity for RAS/BRAF-mutant models facilitates mechanistic and translational research in oncology. Erastin is widely adopted for oxidative stress assays, ferroptosis studies, and protocol optimization in cancer biology (related article). Its use is defined by strict solubility and stability constraints, requiring fresh DMSO solutions and -20°C storage. Benchmarks confirm robust, reproducible induction of ferroptosis under standardized conditions (10 μM, 24 h, HT-1080 cells).

Biological Rationale

Ferroptosis is a regulated cell death modality characterized by iron dependency and lipid peroxidation, distinct from apoptosis or necrosis (Liu et al., 2022). Cancer cells with oncogenic mutations in the RAS (HRAS, KRAS) or BRAF genes are notably susceptible to ferroptosis due to altered redox balance. The cystine/glutamate antiporter system Xc⁻ imports cystine, which is essential for glutathione synthesis—a key antioxidant defense. Inhibition of system Xc⁻ leads to glutathione depletion, accumulation of reactive oxygen species (ROS), and ultimately, ferroptotic cell death. This selectivity underpins the rationale for using Erastin in cancer biology research, especially for targeting therapy-resistant tumors. Ferroptosis also plays a role in neurological disease models, but its enhancement is primarily leveraged for oncology applications (Liu et al., 2022).

Mechanism of Action of Erastin

Erastin exerts its effects through two principal mechanisms:

• Inhibition of system Xc⁻: Erastin blocks the cystine/glutamate antiporter (SLC7A11/xCT), reducing cystine uptake and causing intracellular glutathione depletion. This disrupts cellular redox homeostasis and enhances ROS accumulation (Liu et al., 2022).
• Modulation of VDAC: Erastin binds to the voltage-dependent anion channel on the mitochondrial outer membrane, altering mitochondrial permeability and contributing to oxidative damage.

This dual action triggers caspase-independent, iron-dependent cell death in susceptible tumor cells. Unlike classical apoptosis, ferroptosis is not prevented by caspase inhibitors. The iron dependency is evidenced by the protective effects of iron chelators and ferroptosis inhibitors in Erastin-treated models.

Evidence & Benchmarks

• Erastin induces ferroptosis in HT-1080 fibrosarcoma cells at 10 μM for 24 hours, resulting in robust cell death (Liu et al., 2022, DOI).
• Inhibition of system Xc⁻ by Erastin leads to glutathione depletion and increased ROS, confirmed by biochemical assays and rescue with antioxidants (Liu et al., 2022, DOI).
• Myriocin pretreatment reduces Erastin-induced ferroptosis by activating the HIF-1 pathway, demonstrating specificity of Erastin's oxidative stress mechanism (Liu et al., 2022, DOI).
• Erastin selectively induces death in RAS/BRAF-mutant tumor cells, with minimal impact on wild-type controls under identical conditions (APExBIO).
• Iron chelators (e.g., deferoxamine) and lipid peroxidation inhibitors (e.g., ferrostatin-1) prevent Erastin-induced cell death, confirming iron/lipid ROS dependency (Liu et al., 2022, DOI).

This article extends the mechanistic and workflow guidance of previous summaries (see prior overview) by integrating new findings on HIF-1 pathway modulation and benchmarking protocols.

Applications, Limits & Misconceptions

• Cancer biology research: Erastin is used to study ferroptosis in RAS/BRAF-mutant models, including HT-1080 and engineered human tumor cell lines (related article).
• Oxidative stress assays: Erastin exposure provides a controlled method to induce oxidative, non-apoptotic cell death.
• Drug screening: Erastin is used as a positive control for identifying ferroptosis inhibitors or cytoprotective compounds, as demonstrated by myriocin studies (Liu et al., 2022).
• Pathway interrogation: The compound enables dissection of redox, iron metabolism, and RAS-RAF-MEK signaling interactions.

Common Pitfalls or Misconceptions

• Erastin is not stable in aqueous solution or ethanol; only dissolve in DMSO at ≥10.92 mg/mL with gentle warming (APExBIO).
• Long-term storage of Erastin solutions is not recommended; fresh preparation is essential for reproducibility.
• Ferroptosis induced by Erastin is not prevented by classical apoptosis inhibitors (e.g., caspase inhibitors) but is mitigated by iron chelators or lipid ROS scavengers.
• Erastin's effects are context-dependent; wild-type cells or those lacking oncogenic RAS/BRAF mutations show limited sensitivity (internal guide—this article updates best practices for experimental design).
• Use in neuronal models requires caution; HT22 cells are used for system Xc⁻-mediated ferroptosis studies, but in vivo neurological relevance is still under debate (Liu et al., 2022).

Workflow Integration & Parameters

For optimal use, Erastin should be stored as a solid at -20°C. Prepare solutions in DMSO at concentrations ≥10.92 mg/mL with gentle warming. Immediately before use, dilute to working concentrations (typically 10 μM) in culture medium. Treatment duration is commonly 24 hours for HT-1080 or engineered human tumor cells. Include positive and negative controls, such as ferrostatin-1 or iron chelators, to verify ferroptosis specificity. Monitor cell viability, ROS, and lipid peroxidation markers. Refer to the Erastin product page and the internal guide (protocol resource) for troubleshooting and advanced applications.

Conclusion & Outlook

Erastin, available from APExBIO, is a rigorously validated ferroptosis inducer with defined specificity for RAS/BRAF-mutant cancer models. Its mechanistic clarity and reproducibility position it as an essential reagent for oxidative stress, ferroptosis, and cancer biology research. Ongoing studies refine its application scope, including combinatorial drug screening and translational oncology. For authoritative protocols, product details, and ordering information, visit the APExBIO Erastin page. This article advances prior internal coverage by detailing evidence-based workflow integration and highlighting recent mechanistic insights (see strategic insights).